Herbal medicinal products – Evidence and tradition from a historical perspective

Jütte, Robert; Heinrich, Michael; Helmstädter, Axel; Langhorst, Jost; Meng, Günter; Niebling, Wilhelm; Pommerening, Tanja; Trampisch, Hans–Joachim

doi:10.1016/j.jep.2017.06.047

Cited by 49 publications

(35 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A number of other authors have recently explored the problems related to clinical efficacy of herbal medicinal products (Minuz, Velo, Violi, & Ferro, ), from the point of view of clinical research (Andrew & Izzo, ; Pferschy‐Wenzig & Bauer, ; Varoni, Lodi, & Iriti, ) and regulation (Jütte et al, ). Herbal medicinal products could bring a broad range of beneficial effects, but their efficacy and safety must be assured.…”

Section: Discussionmentioning

confidence: 99%

What phytotherapy needs: Evidence‐based guidelines for better clinical practice

Colalto¹

2017

Phytotherapy Research

View full text Add to dashboard Cite

In recent decades, the pharmacological properties of numerous medicinal plants and opportunities in phytotherapy have been explored through research projects, reviews, and monographs. These studies confirm that medicinal plants offer new approaches to tackling diseases. However, improvement of phytotherapy in clinical practice relies on a number of critical factors. In particular, the studies are very heterogeneous, and results and their interpretation by healthcare workers vary greatly, so preventing consistency in clinical practice. There is therefore a lost opportunity to improve phytotherapy practice, because the work being done and the related systematic reviews cannot act as a body of data on which to base clear clinical recommendations. Approaches such as the Grading of Recommendations Assessment, Development and Evaluation or the Scottish Intercollegiate Guidelines Network methodology could easily help standardise the use of phytotherapy in clinical practice. In this context, evidence-based phytotherapy guidelines could offer new healthcare approaches to the treatment of diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

What phytotherapy needs: Evidence‐based guidelines for better clinical practice

Colalto¹

2017

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Nine countries, China, Korea, India, Indonesia, Malaysia, Myanmar, Sri Lanka, Thailand, and Vietnam, have documented their National Monographs for herbal drugs, while Pharmacopeia is found in Bangladesh, India, Indonesia, Sri Lanka, Thailand, and Vietnam [66,67]. In practice, TCM is more globalized and well-documented [67][68][69][70]. In general, there is increased interest by practitioners to implement good MP management practices-this suggests an urgent need for scientific investigations to inform such a process [71][72][73][74][75].…”

Section: Rules and Structuresmentioning

confidence: 99%

Asian Medicinal Plants’ Production and Utilization Potentials: A Review

2019

View full text Add to dashboard Cite

Medicinal plants research in Asia continues to receive significant national and international attention, particularly concerning its multiple roles in poverty alleviation and health care support. However, scientific information on the institutional arrangements, the potentials of different medicinal plants production systems, and the utilization methods, remain highly fragmented. This incomprehensive information base shades the development of a comprehensive research agenda to improve the current body of knowledge, at least in the context of Asia. To address this impasse and propose future research perspectives, we systematically reviewed 247 journal articles, 15 institutional reports, and 28 book chapters. From the reviews, five key lessons are drawn: (i) Asian medicinal plant production systems demonstrate some dynamics, characterized by a gradual but continuous shift from wild gathering to cultivation, (ii) sub-regional variations exist with regards to the appreciation of medicinal plants potentials for traditional healing, modern healthcare and livelihoods support, (iii) knowledge on the effect of multi-scale institutional arrangements (formal and informal) on medicinal plant management practices is fragmented, (iv) very few studies dwell on the challenges of medicinal plants commercialization, particularly with regards to the role of middlemen, boom–bust cycle, raw material readiness, and product quality, and (v) law enforcement, benefit and knowledge sharing, and research and development should be prioritized to serve the interest of medicinal plants production actors. To further extend the body of knowledge on medicinal plants in Asia, we advance the need for empirical investigations on the performance of medicinal plants production systems and their contribution to livelihoods in diverse institutional contexts.

show abstract

“…The regulation applies to herbal products with a longstanding tradition of use, that have been on the market for at least 30 years, including 15 years in an EU member state. No special assays or trials are required to prove the safety of herbal medicines, but proof that the product is not harmful is compulsory (European Commission, 2004;Jütte et al, 2017). Since 2004, the EU Directive 2004/24/EC has been incorporated into national legal systems to increase the safety of traditional herbal medicines and to facilitate their free movement by harmonising previous national regulatory frameworks (Vlietinck et al, 2009;Jütte et al, 2017).…”

Section: Regulatory Status Of Herbal Productsmentioning

confidence: 99%

“…No special assays or trials are required to prove the safety of herbal medicines, but proof that the product is not harmful is compulsory (European Commission, 2004;Jütte et al, 2017). Since 2004, the EU Directive 2004/24/EC has been incorporated into national legal systems to increase the safety of traditional herbal medicines and to facilitate their free movement by harmonising previous national regulatory frameworks (Vlietinck et al, 2009;Jütte et al, 2017). The Herbal Medicinal Products Committee (HMPC) is the European Medicines Agency's (EMA's) committee responsible for establishing monographs on the therapeutic uses and the safety of medicinal products, with the pharmacovigilance of the marketed herbal medicines being a regulatory requirement falling under the full responsibility of manufacturers and suppliers.…”

Section: Regulatory Status Of Herbal Productsmentioning

confidence: 99%

Benefits and Limitations of DNA Barcoding and Metabarcoding in Herbal Product Authentication

Raclariu

Heinrich

Ichim

et al. 2017

Phytochemical Analysis

Self Cite

157

126

View full text Add to dashboard Cite

IntroductionHerbal medicines play an important role globally in the health care sector and in industrialised countries they are often considered as an alternative to mono‐substance medicines. Current quality and authentication assessment methods rely mainly on morphology and analytical phytochemistry‐based methods detailed in pharmacopoeias. Herbal products however are often highly processed with numerous ingredients, and even if these analytical methods are accurate for quality control of specific lead or marker compounds, they are of limited suitability for the authentication of biological ingredients.ObjectiveTo review the benefits and limitations of DNA barcoding and metabarcoding in complementing current herbal product authentication.MethodRecent literature relating to DNA based authentication of medicinal plants, herbal medicines and products are summarised to provide a basic understanding of how DNA barcoding and metabarcoding can be applied to this field.ResultsDifferent methods of quality control and authentication have varying resolution and usefulness along the value chain of these products. DNA barcoding can be used for authenticating products based on single herbal ingredients and DNA metabarcoding for assessment of species diversity in processed products, and both methods should be used in combination with appropriate hyphenated chemical methods for quality control.ConclusionsDNA barcoding and metabarcoding have potential in the context of quality control of both well and poorly regulated supply systems. Standardisation of protocols for DNA barcoding and DNA sequence‐based identification are necessary before DNA‐based biological methods can be implemented as routine analytical approaches and approved by the competent authorities for use in regulated procedures. © 2017 The Authors. Phytochemical Analysis Published by John Wiley & Sons Ltd.

show abstract

Herbal medicinal products – Evidence and tradition from a historical perspective

Cited by 49 publications

References 13 publications

What phytotherapy needs: Evidence‐based guidelines for better clinical practice

What phytotherapy needs: Evidence‐based guidelines for better clinical practice

Asian Medicinal Plants’ Production and Utilization Potentials: A Review

Benefits and Limitations of DNA Barcoding and Metabarcoding in Herbal Product Authentication

Contact Info

Product

Resources

About